Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Last updated May 26, 2025
Status:
Concluded with an LOI
Manufacturer:
Nora Pharma Inc.
Indication:
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Last updated May 23, 2025
Status:
Concluded with an LOI
Manufacturer:
Horizon Therapeutics Canada
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated May 12, 2025
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Last updated May 7, 2025
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Hidradenitis Suppurativa
Last updated May 1, 2025
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Ulcerative Colitis
Last updated April 29, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Last updated April 28, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
Last updated April 25, 2025
Status:
Concluded with an LOI
Manufacturer:
Jamp Pharma Corporation
Indication:
Ulcerative Colitis and Crohn's Disease
Last updated April 25, 2025
Enhertu (concluded with pTAP LOI) (trastuzumab deruxtecan)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen
Last updated April 24, 2025